Esperion Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Esperion Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.19. The average 1-year stock price forecast is 1.92% higher than the current stock price, while the lowest is $3.16 (+0.96%) and the highest is $3.28 (+4.79%).

Price Target: $3.19 (+1.92%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$3.16	$3.19	$3.16	$3.28
Change	+0.96%	+1.92%	+0.96%	+4.79%

* Price targets were last updated on May 4, 2026.

Analyst Ratings

The average analyst rating for Esperion Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	2	3	0
Buy	3	3	3	3	3	0
Hold	1	1	1	1	1	6
Sell	1	1	1	1	1	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	7	8	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Serge Belanger Needham	Needham	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 12, 2026
Dennis Ding Jefferies	Jefferies	Hold Downgrades $3.28	Hold	Downgrades	$3.28	+4.79%	May 4, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Hold Downgrades $3.16	Hold	Downgrades	$3.16	+0.96%	May 4, 2026
David Amsellem Piper Sandler	Piper Sandler	Hold Downgrades $9 → $3.16	Hold	Downgrades	$9 → $3.16	+0.96%	May 1, 2026
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Downgrades $3.16	Hold	Downgrades	$3.16	+0.96%	May 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

337.60M

from 403.14M

-16.26%

from 403.14M

Revenue Next Year

456.69M

from 337.60M

35.28%

from 337.60M

EPS This Year

-0.21

from -0.11

EPS Next Year

0.29

from -0.21

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	78.45M	75.48M	116.33M	332.31M	403.14M	337.60M
Revenue Growth	-65.53%	-3.79%	54.14%	185.66%	21.31%	-16.26%
Gross Profit	-41.75M	-70.42M	-13.04M	217.48M	226.06M	261.64M
Gross Margin	-53.21%	-93.30%	-11.21%	65.44%	56.08%	77.50%
Operating Income	-213.48M	-179.50M	-155.56M	54.40M	60.27M	79.93M
Net Income	-269.11M	-233.66M	-209.25M	-51.75M	-22.68M	-52.10M
EPS	-	-	-	-	-0.11	-0.21
Free Cash Flow	-192.19M	-135.56M	-129.64M	-65.72M	-52.59M	53.00M
No. Analysts	-	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	337.6M
Avg	337.6M
Low	337.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-16.3%
Avg	-16.3%
Low	-16.3%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.21
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-